All In Biotech

NDA 017106 · Mmt

Atropen

Atropine · Intramuscular · Anticholinergic; Cholinergic Muscarinic Antagonist

Priority reviewDiscontinued

Last checked: Nov 20, 2026Latest source record: Nov 20, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1973

May 15, 1973

Approved uses

2

Original approval plus efficacy supplements

Registered trials

414

74 Phase 3, 30 recruiting

FAERS reports

8,429

7,748 serious, 1,634 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 15, 2022.

ATROPEN is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having cholinesterase activity as well as organophosphorus or carbamate insecticides in adult and pediatric patients. ATROPEN is a cholinergic muscarinic antagonist indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having cholinesterase activity as well as organophosphorus or carbamate insecticides in adult and pediatric patients. ( 1 )

Mechanism: Atropine competitively blocks the effects of acetylcholine, including excess acetylcholine due to organophosphorus poisoning, at muscarinic cholinergic receptors on smooth muscle, cardiac muscle, secretory gland cells, and in peripheral autonomic ganglia and the central nervous system.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 19, 2003 Supplement 28 · Efficacy · priority review LetterLabel
  • May 15, 1973 Original approval · Type 5 - New Formulation or New Manufacturer · priority review
4 products under this application
  • ATROPEN · ATROPINE EQ 0.25MG SULFATE/0.3ML · SOLUTION, INTRAMUSCULAR · Discontinued
  • ATROPEN · ATROPINE EQ 1MG SULFATE/0.7ML · SOLUTION, INTRAMUSCULAR · Discontinued
  • ATROPEN · ATROPINE EQ 0.5MG SULFATE/0.7ML · SOLUTION, INTRAMUSCULAR · Discontinued
  • ATROPEN · ATROPINE EQ 2MG SULFATE/0.7ML · SOLUTION, INTRAMUSCULAR · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Atropine" as an intervention, any sponsor and status, largest first.

All 414 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective634
  • off label use595
  • diarrhoea591
  • fatigue538
  • nausea522
  • hypotension506
  • death460
  • dyspnoea436
  • bradycardia399
  • pain394
  • vomiting375
  • cardiac arrest315

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004194
2005156
2006170
2007108
2008168
2009177
2010174
2011318
2012509
2013223
2014241
2015388
2016405
2017367
2018462
2019509
2020569
2021555
2022542
2023592
2024555
2025513
2026531

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,885 on PubMed

Sponsor: Mmt

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.